



INITIATING COVERAGE JUBILANT INGREVIA LTD

Entering The New Era of Growth

We are initiating coverage on Jubilant Ingrevia Ltd (JIL) with a **BUY** recommendation and a Target Price of 800/Share, implying an upside of 21% from the CMP. JIL is a global integrated life science products provider, holding leadership positions in Pyridine and Vitamin B3. The company is currently executing a structural pivot, moving away from commoditised chemical intermediates toward high-margin Specialty Chemicals and CDMO services. With a peak annual revenue potential of Rs 1,400 Cr from new molecules and the commencement of a major \$300 Mn agro-innovator contract, JIL is at a critical inflection point for a new growth phase.

Investment Thesis

- Strategic Transformation:** JIL is undergoing a strategic transformation from a commodity-heavy business to a specialised niche player, targeting to increase the share of specialty products across segments. Under its strategic transformation initiative named 'Pinnacle345', the company is aiming for three times revenue growth and four times EBITDA growth in the next 4-5 years (by FY30).
- Well-timed Capacity Addition:** The company's strategic shift is supported by around Rs 2,000 Cr capex undertaken over the last three years, which has established new multi-purpose plants (MPPs) and expanded Vitamin B3 capacities, positioning the firm for a multi-year compounding cycle. This capacity enhancement comes at the right time, as industry overcapacity in China is showing signs of abating, while the US-India agreement and EU FTA improve export competitiveness.
- Exponential Growth in Specialty Chemicals followed closely by Nutrition:** JIL is strategically positioning its Specialty Chemicals division, led by its CDMO division, as its central growth catalyst, broadening its operational footprint across pharmaceuticals, agrochemicals, human nutrition and the high-barrier semiconductor chemicals sector. Near-term revenue acceleration is underpinned by critical strategic wins, most notably a landmark \$300 Mn (approximately Rs 2,500 Cr) long-term agrochemical CDMO contract and the successful onboarding of a patented innovator molecule. The Nutrition segment is also gaining momentum, aided by incremental capacities in high-purity cosmetic-grade niacinamide and supplement ingredient choline. The segment is witnessing encouraging customer interest and is expected to lead to sizeable orders in FY27 and beyond. JIL offers highly resilient earnings visibility, backed by a robust development funnel of 16 confirmed molecules and over 100 prospective opportunities. These collectively represent a peak revenue potential of Rs 3,500 Cr. Furthermore, structural downside risks are effectively mitigated through a minimum offtake commitments in its large-scale contracts. Supported by firm purchase orders securing over 70% of its near-term pipeline, JIL's CDMO revenues in particular are on a definitive trajectory to multiply 5x by FY29/30 (from its Dec'24 baseline). Overall, the strong execution across Specialty Chemicals and Nutrition segments reinforces JIL's long-term growth trajectory and margin expansion outlook.
- Margin Expansion:** The company has set a threshold margin criterion of 20% EBITDA and ROCE of 20% plus for every new capex and has aligned recent capacity additions accordingly. The newer capacities are expected to witness a steady ramp-up over the next two years, contributing high-margin revenue with EBITDA margins close to 20%. Overall, JIL is pivoting toward high-margin engines in Fine Chemicals, CDMO, and specialized Nutrition, and expects margins to reach the 18–20% range over the next five years.
- Improving Return Ratios:** The company's capex initiatives are guided by stringent profitability/returns criteria. As these newly commissioned assets ramp up and operating leverage kicks in, return ratios are expected to expand significantly, with ROCE nearing ~15% by FY27-28.

Valuation & Recommendation

JIL's Revenue/EBITDA/PAT are expected to grow at a CAGR of 13%/20%/22% over FY25-28E, driven by strategic capex and product portfolio expansion. We value Jubilant Ingrevia on an SOTP basis, arriving at a Target Price of Rs 800/share. The valuation reflects the improving quality of earnings (higher contribution from Specialty/CDMO), reduced cyclicality, and strong ROCE trajectory.

Key Financials (Consolidated)

| (Rs Cr) | FY25 | FY26E | FY27E | FY28E |
|---------------|-------|-------|-------|-------|
| Net Sales | 4,178 | 4,329 | 5,058 | 5,982 |
| EBITDA | 519 | 546 | 724 | 887 |
| Net Profit | 251 | 286 | 358 | 451 |
| EPS (Rs) | 15.8 | 18.0 | 22.5 | 28.3 |
| P/E (x) | 41.7 | 36.7 | 29.3 | 23.3 |
| EV/EBITDA (x) | 21 | 21 | 16 | 13 |
| ROE (%) | 9% | 9% | 11% | 12% |
| ROCE (%) | 11% | 11% | 13% | 15% |

Source: Company, Axis Securities Research

(CMP as of 21st April, 2026)

| | |
|-----------------------------|----------|
| CMP (Rs) | 659 |
| Upside /Downside (%) | 21% |
| High/Low (Rs) | 852/535 |
| Market cap (Cr) | 10,574 |
| Avg. daily vol. (1 m) Shrs. | 1,90,063 |
| No. of shares (Cr) | 15.9 |


Shareholding Pattern (%)

| | Sept-25 | Dec-25 | Mar-26 |
|----------|---------|--------|--------|
| Promoter | 45.22 | 45.22 | 45.22 |
| FII's | 5.96 | 6.15 | 6.49 |
| DII's | 23.04 | 24.00 | 24.76 |
| Govt. | 0.02 | 0.02 | 0.02 |
| Public | 24.94 | 23.80 | 22.53 |
| Others | 0.82 | 0.80 | 0.98 |

Financial & Valuations

| Y/E Mar (Rs Cr) | FY26E | FY27E | FY28E |
|-----------------|-------|-------|-------|
| Net Sales | 4,329 | 5,058 | 5,982 |
| EBITDA | 546 | 724 | 887 |
| Net Profit | 286 | 358 | 451 |
| EPS (Rs) | 18.0 | 22.5 | 28.3 |
| PER (x) | 36.7 | 29.3 | 23.3 |
| EV/EBITDA (x) | 21 | 16 | 13 |
| ROE (%) | 9% | 11% | 12% |
| ROCE (%) | 11% | 13% | 15% |

Relative Performance



Source: Ace Equity, Axis Securities Research


Shivani More

Research Analyst

Email: shivani.more@axissecurities.in

Jubilant Ingrevia's Story in Charts

Exhibit 1: Quarterly Segmental Revenue Breakup



Source: Company, Axis Securities Research

Exhibit 2: Increased Capex Intensity in the last 3 years





Exhibit 3: Revenue Growth to Accelerate Post Capex



Source: Company, Axis Securities Research

Exhibit 4: Revenue Share of Specialty Chemicals on Rise






Exhibit 5: EBITDA Margins to Improve in NHS & Intermediates, Specialty to remain steady



Source: Company, Axis Securities Research

Exhibit 6: Leading to Absolute EBITDA & EBITDA Margin growth



About the Company - JUBILANT INGREVIA LTD.

Jubilant Ingrevia is a global leader in specialty chemicals and life sciences, recently demerged from Jubilant Life Sciences to sharpen its focus on innovation-led manufacturing. Operating through a high-scale, integrated model, the company has established strong market moats, particularly in Pyridine derivatives and Vitamin B3. Its broad portfolio of products and services addresses essential requirements across multiple international value chains.

Born from the demerger of Jubilant Life Sciences in 2021, Jubilant Ingrevia Ltd carries a rich legacy of over 45 years in the chemical industry.

Core Business Segments

The company operates across three strategic pillars, heavily supported by backward integration, where raw materials from one segment feed into the next:

- **Specialty Chemicals:** The company's highest-margin engine, focused on Pyridine and Picolines. It is the global low-cost leader in this space, serving the majority of top pharmaceutical and agrochemical innovators worldwide.
- **Nutrition & Health Solutions:** A segment where Jubilant is a dominant global player, specifically as the world's second-largest producer of Vitamin B3 (Niacinamide).
- **Chemical Intermediates:** Focused on high-volume Acetyls like Acetic Anhydride and Ethyl Acetate. While more cyclical than specialty products, this segment provides a stable revenue base and essential feedstock for the higher-value divisions.

Exhibit 7: Business Verticals



Source: Company, Axis Securities Research

The company's operations extend to more than 50 countries, serving over 1,500 customers, including leading global innovators and Fortune 500 companies. With its technical expertise and long track record, JIL has positioned itself as a reliable supply chain partner. Its manufacturing facilities are compliant with global standards such as cGMP, REACH, US FDA, and ISO. The company has also developed strong innovation capabilities with an in-house team of scientists and technologists possessing expertise in proprietary products, custom synthesis initiatives, and sustainable chemistry solutions.

Exhibit 8: World Class Manufacturing Facilities



Source: Company, Axis Securities Research

Manufacturing Footprint: JIL operates through five manufacturing facilities in India:

1. **Gajraula (UP):** Integrated facility for Specialty Chemicals & Chemical Intermediates (463 acres).
2. **Bharuch (Gujarat):** CDMO & Fine Chemicals, Nutrition (310 acres).
3. **Nira (Maharashtra):** Chemical Intermediates (144 acres).
4. **Savli (Gujarat):** Animal Nutrition & Health Solutions (109 acres).
5. **Ambernath (Maharashtra):** Microbial Control Solutions (3.5 acres).

These sites are supported by three R&D centers (Noida and Gajraula), employing ~150 scientists, including 30 PhDs. During FY25, the company significantly strengthened its research and development capabilities by expanding its R&D workforce to 150 skilled scientists, including 30 highly specialized PnD experts, across three established research centers. This expansion was driven by ongoing talent additions, with a particular focus on the newly commissioned R&D facility in Greater Noida. The enhanced team and infrastructure reflect the company's continued emphasis on accelerating innovation and building a scalable, future-ready R&D platform.

Business Segments and Key Growth Drivers

Jubilant Ingrevia's business is classified under three segments. The speciality chemicals segment is the largest in revenue terms, followed by Chemical Intermediaries, and Nutrition & Health Solutions.

Operates across three segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediaries.

Exhibit 9: Jubilant Ingrevia's Business Segments

| Specialty Chemicals | Nutrition & Health Solutions | Chemical Intermediates |
|---|--|--|
| <ul style="list-style-type: none"> ■ Overview: High-value, margin-accretive segment including Pyridine & Picolines, Fine Chemicals, and CDMO services. ■ Products: Pyridine & Picolines, Cyanopyridines, Piperidine, Fine Chemicals (CDMO), Diketene Derivatives, etc. ■ Applications: Agrochemicals, pharmaceuticals, Dyestuffs & textiles, Personal care & cosmetics, Electronics, Oil Field Applications ■ FY25 Revenue: Rs. 1,818 Cr (44% of Revenue) ■ Export: Domestic Mix: 53:47 ■ FY25 EBIT: Rs. 423 Cr ■ EBIT %: 23% | <ul style="list-style-type: none"> ■ Overview: Focuses on Animal Nutrition and Human Nutrition. ■ Products: Vitamin B3 (Niacinamide/Niacin), Vitamin B4 (Choline Chloride), specialty Premixes, etc. ■ Applications: Animal Nutrition, Human Nutrition, Personal Care, Pharmaceutics, Others ■ FY25 Revenue: Rs. 747 Cr (18% of Revenue) ■ Export: Domestic Mix: 74:26 ■ FY25 EBIT: Rs. 101 Cr ■ EBIT %: 14% | <ul style="list-style-type: none"> ■ Overview: The chemical Intermediates segment providing feedstock integration for specialty segments. ■ Products: Acetic Anhydride, Ethyl Acetate, Propionic Anhydride, Industrial Alcohol, etc. ■ Applications: Pharmaceuticals, Agrochemicals, Food & Nutrition. ■ FY25 Revenue: Rs. 1612 Cr (39% of Revenue) ■ Export: Domestic Mix: 29:71 ■ FY25 EBIT: Rs. 108 Cr ■ EBIT %: 7% |

Source: Company, Axis Securities Research

Specialty Chemicals Segment: Core Earnings Engine

Jubilant Ingrevia has established a dominant global position in the Pyridine and Picolines market by leveraging a backward integration strategy. By producing its own Acetaldehyde from bio-based Ethanol, the company exercises control across the value chain, from raw material to finished product. This capability has enabled the development of a portfolio of over 70 commercial products. The company’s Specialty Chemicals division serves industries including pharmaceuticals, agrochemicals, nutrition, and personal care. With over four decades of experience, the business has progressed to complex chemistry platforms. A key growth driver is its expansion into Diketene Derivatives, where it has introduced products such as Ethyl Acetoacetate and Tert-butyl Acetoacetate.

To enhance long-term profitability, the segment operates through three verticals: Bio-Pyridine, Fine Chemicals, and CDMO (Contract Development and Manufacturing). This structure enables the company to address diverse market requirements while leveraging regulatory expertise and research capabilities.

Specialty Chemicals segment serves as its core earnings driver, supported by a backward-integrated Bio-Pyridine platform, expanding high-value product portfolio (including Diketenes), and strong growth momentum in Fine Chemicals and CDMO under the “Pinnacle Vision” strategy.


Market Leadership and Portfolio Evolution

The company has strengthened its position in specialty chemicals, particularly within the Pyridine market, by expanding its product range, scaling the Diketene business, and strengthening CDMO offerings. By entering new chemistry platforms, the company has moved toward a more specialized business model.

Key Sub-Segments

- Pyridine & Picolines:** The Pyridine and Picolines segment remains a core strength, with the company being a producer of “Bio-Pyridine” outside China. This position enabled it to benefit from demand recovery and improved pricing in 2025. The company is expanding into segments such as electronics and oilfield chemicals to diversify revenue streams.
- Fine Chemicals:** In the Fine Chemicals and CDMO verticals, the company is focused on scaling up capabilities and expanding production capacity. The expansion of its Diketene facility in Gajraula has achieved high utilization levels.
- CDMO:** The CDMO business is growing rapidly by providing custom manufacturing for global innovators. This includes late-stage pharmaceutical programs, newly commissioned agrochemical facilities, and an emerging focus on high-purity molecules for the semiconductor industry.

Exhibit 10: Increasing Contribution of Specialty Chemicals to the Overall EBITDA



Source: Company, Axis Securities Research

Key Segment Growth Drivers

After a long period of slow demand due to high inventory levels, the global specialty chemicals market is showing signs of stabilising. The company is seeing a recovery in sales volumes and export demand from key markets like the US, Europe, and Japan. This recovery is supported by investments in new factories and infrastructure for custom manufacturing (CDMO) and Diketenes.

Under the “Pinnacle Vision” strategy, the company has set a target to more than triple its specialty chemicals revenue by 2030 while sustaining profit margins of over 25%. In the third quarter of 2026, the company reported revenue growth with margins of 25%, driven by traction in Fine Chemicals and CDMO sales.

Within the specialty chemicals segment, the company expects its Fine Chemicals business to double by FY30 and its CDMO business to grow fivefold by 2027. Growth is projected to accelerate in 2026 as the company commences deliveries under a new CDMO contract and commissions a production facility in Gajraula. The company is expanding into segments such as semiconductors and cosmetics. Concurrently, it is prioritizing cost optimization and higher asset utilization to improve operating leverage.

Exhibit 11: Targeting 3x+ Revenue with 25% margins by FY30 under Pinnacle Vision



Source: Company, Axis Securities Research


Nutrition & Health Solutions: Margin-Accretive Growth Platform

The Nutrition & Health Solutions (N&HS) business provides ingredients for human and animal health, as well as pharmaceutical and personal care industries. Key offerings include Vitamin B3 (Niacin & Niacinamide) and Choline Chloride.

JIL’s manufacturing facility is fully backward integrated, and the company has received NABL accreditation for its laboratories. This enables control over the manufacturing process and reduces dependence on external suppliers and labs.

Nutrition & Health Solutions segment is a margin-accretive growth platform driven by its leadership in Vitamin B3 and Choline Chloride, expanding presence in premium human nutrition and cosmetic applications, and supported by strong backward integration under the Pinnacle strategy.

Exhibit 12: Jubilant Ingrevia's Integrated Process for Niacinamide & Niacin



Source: Company, Axis Securities Research

The segment has historically been anchored in animal nutrition and is now expanding into human nutrition and cosmetic applications.

This segment is organized into three specialized pillars: Nutrition & Health Ingredients, Human Nutrition Solutions, and Animal Nutrition Solutions.

- Vitamin B4 and Vitamin 3 (Nutritional & Health Ingredients):** JIL has market share in India in Vitamin B4 (Choline Chloride), catering to applications like feed, food, pharmaceuticals, and dye manufacturing. It provides Vitamin B3 for applications like animal nutrition, human nutrition, and personal care. The company also offers nutritional ingredients like Riboflavin Phosphate Sodium (RPS), Inositol Hexa-Nicotinate, Chromium Picolinate, and Zinc Picolinate.
- Human Nutrition & Health:** The human nutrition platform caters to dietary supplements, cosmetics, bakery, beverages, and functional foods. Key offerings include niacinamide, choline derivatives, chromium and zinc picolinate, and vitamin B2 derivatives. The company benefits from backward integration in several products.
- Animal Nutrition & Health:** This vertical supplies feed additives across poultry, dairy, aquaculture, and pet nutrition markets. The portfolio includes vitamin B3, choline chloride, plant-based liver health solutions, and premixes, serving over 450 customers.

Key Segment Growth Drivers

Management remains focused on expanding human nutrition and cosmetic-grade offerings. The recently commissioned cGMP capacity for cosmetic-grade Niacinamide is being ramped up and is expected to drive volume growth over the next two years. Under the Pinnacle strategy, the segment is expected to deliver steady growth. By FY30, revenues are targeted to exceed Rs 2000 Cr with EBITDA margins of 18–20%.

Exhibit 13: Targeting revenue in excess of Rs 2,000 Cr, and ~600bps margin improvement by FY30



Source: Company, Axis Securities Research

Chemical Intermediates: Cyclical Headwinds, Structural Strength Intact

The Chemical Intermediates business provides stable cash flows and operates with negative working capital, supporting investments across segments. Key products in this segment are commoditized and influenced by supply-demand dynamics. Their performance is cyclical, with limited scope for pricing premium. However, JIL has demonstrated performance supported by customer relationships and integrated capabilities. These products remain critical for manufacturing processes across industries.

The company operates five manufacturing facilities across India, supported by global storage hubs in Europe and South Korea. The segment is built on acetyl and ketene chemistry platforms and caters to external customers and internal operations. The Chemical Intermediates portfolio includes Acetyl Products and Specialty Ethanol. JIL has capacity to produce Acetyls and Alcohol Derivatives from agro-based feedstock and supplies specialty-grade Alcohol to agrochemical and pharmaceutical customers. JIL is regarded as the world's largest producer of Bio Acetaldehyde.

Chemical Intermediates segment provides stable cash flows and value-chain integration despite cyclical pricing pressures, supported by global leadership in bio-based acetyl chemicals, diversified end-use demand, and capacity expansion under the Pinnacle Vision strategy.

Exhibit 14: Products of Chemical Intermediaries



Source: Company, Axis Securities Research

These products serve as the "building blocks" for a vast range of everyday products, from life-saving medicines to the packaging that keeps food fresh. The products offered can be broadly classified into three categories based on usage:


- **Large-Scale Essentials:** This group includes products like Acetic Anhydride, used in pharmaceuticals, agrochemicals, nutrition, polymers, dyes, and aromatics. A significant portion of demand originates from the pharmaceutical sector, particularly for paracetamol manufacturing. Ethyl Acetate serves as a solvent for inks and glues used in food packaging and paints.
- **The Bio-based offerings:** The company utilizes ethanol to produce Bio Acetic Acid and Bio Acetaldehyde. These variants are used in food and fragrance industries and carry certifications including Kosher and Halal.
- **Niche Products:** The company manufactures chemicals such as Propionic Anhydride and Formaldehyde for pharmaceuticals, agrochemicals, resins, and adhesives.

The company operates integrated facilities, enabling in-house production of key raw materials such as Bio Acetaldehyde, supporting cost efficiency and supply stability. Diversification across industries, including pharmaceuticals, food, construction, and agriculture, reduces dependence on any single segment.

Key Growth Drivers

JIL holds a diversified portfolio in Chemical Intermediates with positions in several products. The company plans to expand its market share and geographical footprint through volume expansion and customer engagement. The Acetic Anhydride facility, commissioned in FY24, is expected to ramp up operations. The company is implementing cost reduction initiatives to manage margin headwinds. Under the Pinnacle Vision, JIL is targeting revenues in excess of Rs 2,500 Cr with margins in the 10–12% range by FY30.

Exhibit 15: Looking to Regain Momentum with Steady Growth



Source: Company, Axis Securities Research

Key Competitive Strengths

Global Leadership in Pyridine, Derivatives, and Acetic Anhydride

The company ranks among the top two global producers of pyridine and holds leadership positions in several downstream derivatives, including beta picoline, lutidines, and 3-cyanopyridine. Importantly, it is the only scaled non-Chinese supplier in the global pyridine market, offering a strategically attractive alternative for multinational customers. The diketene derivatives platform is also scaling rapidly, with management targeting a top-three global position. This leadership is supported by long-standing chemistry expertise, continuous process improvements, and strong regulatory credentials, enabling the company to serve global pharmaceutical, agrochemical, and specialty chemical customers reliably.

Strong Position in Vitamin B3 and B4

The company is the world's second-largest producer of Vitamin B3 and maintains leadership in the domestic Vitamin B4 market, catering to both human and animal nutrition. Backward integration into beta picoline provides a structural cost advantage and supply security, while a wide range of grades strengthens its relevance across food, feed, pharmaceutical, and personal care applications.

Scalable CDMO and Custom Manufacturing Capabilities

The CDMO platform offers integrated services across pharmaceuticals, agrochemicals, and specialty chemicals, covering process development to commercial manufacturing under both GMP and non-GMP regimes. Deep expertise in complex and hazardous chemistries, multi-step synthesis, and advanced reactions positions the company well to capture the growing trend of global outsourcing. Expansion into semiconductor-linked intermediates, including E-pyridines, further aligns the CDMO portfolio with high-technology and strategically important end markets.

Vertically Integrated Operating Model

The company follows a fully integrated manufacturing structure across its Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates businesses. This vertical integration enables in-house production of key feedstocks and intermediates, supporting cost efficiency, quality consistency, operational control, and the ability to move up the value chain into higher-margin products. The company operates large-scale, multi-purpose manufacturing facilities in India capable of handling complex chemistries and high-volume production. Continuous automation and process enhancements drive high yields, lower waste, and consistent delivery performance, supporting global customer requirements.

Diversified Global Customer Base and Business Mix

With operations spanning more than 50 countries and a customer base exceeding 1,500 clients, including leading global players, the company benefits from broad market access and strong customer relationships. Its global distribution capabilities, regulatory compliance track record, and customer-focused approach support high retention rates and long-term engagement. Additionally, presence across three complementary segments, Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates, provides inherent diversification. This balanced portfolio reduces exposure to single-sector cyclicity while creating multiple growth drivers across regulated, consumer-facing, and industrial markets.

Sustainability-Focused Manufacturing

Sustainability remains embedded in the operating model, with a strong emphasis on bio-based inputs, water recycling, waste management, and energy efficiency. The company is Responsible Care certified and ranks strongly on global ESG benchmarks, including EcoVadis and the S&P Dow Jones Sustainability Index, reflecting its commitment to environmentally responsible growth.

Jubilant Ingrevia's fully integrated value chain provides structural cost efficiency, quality consistency, and operational leverage, enabling sustained innovation and long-term growth across global markets.

Peer Comparison/Key Competitors

Jubilant Ingrevia features a highly integrated business structure divided into three core segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. Given its broad product portfolio and robust backward integration—spanning from raw molasses to advanced derivatives—the company lacks a direct equivalent among listed Indian peers. Consequently, it faces a diverse mix of domestic and international competitors tailored to each specific business line. A breakdown of the competitive landscape by segment is outlined below:

Specialty Chemicals (Pyridine, Picolines, Diketene, and CDMO):

This segment is characterised by complex chemistries and long customer qualification cycles (3–5 years).

- **Global Peers:** The global pyridine and picoline market is highly consolidated outside of China. Jubilant's primary global competitors include **Arxada** (formerly Lonza) and **Aurorium** (formerly Vertellus), alongside Chinese manufacturers.
- **Domestic Peers:** In the Diketene derivatives space, **Laxmi Organics** is the dominant incumbent. Jubilant is aggressively expanding here to capture import substitution and export opportunities, alongside emerging players like **Valiant Organics**. For the CDMO business, peers include established custom synthesis players like **Aarti Industries**, **SRF**, and **PI Industries**, though Jubilant differentiates itself through its pyridine and ketene chemistry platforms.

Nutrition & Health Solutions (Vitamins & Premixes)

Jubilant is the world's second-largest producer of Vitamin B3 (Niacinamide) and a domestic leader in Vitamin B4 (Choline Chloride).

- **Global Peers:** Competes with global life-science and chemical giants such as **DSM-Firmenich**, **Arxada**, **BASF SE**, **Kemin Industries**, and **Glanbia PLC**.
- **Domestic Peers:** Key Indian competitors in the feed and nutrition space include **Balaji Amines**, **Lasons India**, **Camlin Fine Sciences**, and **Avitech Nutrition**.

Chemical Intermediates (Acetic Anhydride, Ethyl Acetate, Acetic Acid)

This segment is highly commoditized and relies heavily on scale and global supply-demand dynamics (particularly Chinese capacities).

- **Global Peers:** **Celanese Corporation**, **Eastman Chemical**, **Daicel Corporation**, **INEOS**, and **Sipchem**.
- **Domestic Peers:** **Laxmi Organics**, **Gujarat Narmada Valley Fertilizers & Chemicals (GNFC)**, **EID Parry**, **Godavari Biorefineries**, and **Indian Oil Corporation (IOCL)**.

Despite massive capacity dumping from Chinese manufacturers and stiff competition in various segments globally, Jubilant Ingrevia protects its margins and market share through three structural advantages:

- **Unmatched Cost Leadership:** While Chinese pyridine plants run at sub-optimal 40–50% utilization, Jubilant operates at 80–85% utilization and uses renewable bio-ethanol (molasses). Its cost-optimization programs delivered over Rs 1.2 bn in savings in FY25..
- **End-to-End Vertical Integration:** Integrated from molasses to high-value chemicals and vitamins. By internally consuming ~45% of its Pyridine and Picoline output, the company ensures supply security and captures higher value.
- **High Entry Barriers & Customer Stickiness:** Supplier qualification takes 3 to 5 years, leading to strong customer stickiness.

Management Team

| Name | Experience |
|---|---|
| Mr. Shyam S. Bhartia <i>Chairman</i> | <ul style="list-style-type: none"> Mr. Shyam S. Bhartia is the Chairman of Jubilant Pharmova Limited, Jubilant Ingrevia Limited, and Jubilant FoodWorks Limited. He is also Chairman and Managing Director of Jubilant Pharma Limited, Singapore. He holds a bachelor's degree in commerce from St. Xavier's College, Calcutta University, and is a qualified cost and works accountant and a fellow member of the Institute of Cost and Works Accountants of India (ICWAI). |
| Mr. Hari S. Bhartia <i>Co-Chairman and Whole Time Director</i> | <ul style="list-style-type: none"> Mr. Hari S Bhartia is the Founder and Co-Chairman of Jubilant Bhartia Group. He is also the Co-Chairman, Non-Executive Director of Jubilant Pharmova Limited, Co-Chairman and Whole Time Director of Jubilant Ingrevia Limited & Co-Chairman of Jubilant FoodWorks Limited. He is a Chemical Engineering Graduate from the Indian Institute of Technology (IIT), Delhi. With over four decades of experience. |
| Mr. Deepak Jain <i>CEO and Managing Director</i> | <ul style="list-style-type: none"> Mr. Deepak Jain has more than 20 years of rich & diverse global experience with Bain & Company, where he has been working as a Senior Partner responsible for the APAC Advanced Manufacturing & Services practice covering Automotive, Chemical, and Cement industries. |
| Mrs. Sudha Pillai <i>Independent Director</i> | <ul style="list-style-type: none"> Mrs. Sudha Pillai is an Alumna of Panjab University with a BA (Hons) degree in English Literature, securing First Rank and Gold Medal, and a master's degree in Psychology, also securing First Rank and another Gold Medal. She also has a master's degree in Public Administration from Harvard University, USA, with special areas of interest in the Impact of Foreign Direct Investment. |
| Mr. Vijay Srivastava <i>Chief of Operations & Whole – Time Director</i> | <ul style="list-style-type: none"> Vijay Srivastava holds a Bachelor's degree in Chemical Engineering from IIT Kharagpur and an MBA from SCDL Pune. He is a Six Sigma Black Belt and holds CPIM certification from APICS. He has more than 26 years of experience in Manufacturing across various industries, including Petrochemicals, Engineering Polymers, Agro Chemicals, Organic & Inorganic Intermediates. |
| Mr. Sushil Kumar Roongta <i>Independent Director</i> | <ul style="list-style-type: none"> Mr. Sushil Kumar Roongta is an Electrical Engineer from BITS, Pilani, and a PG Diploma in Business Management (International Trade) from IIFT, Delhi. He has over 45 years of illustrious background in the industry. He was the Executive Chairman of SAIL during 2006-2010 and also served as the Managing Director of the Aluminium & Power business of Vedanta group (2011-2015). |
| Mr. Arun Seth <i>Independent Director</i> | <ul style="list-style-type: none"> Mr. Arun Seth holds a bachelor's degree in engineering from the Indian Institute of Technology, Kanpur, as well as a Master's in Business Administration from the Indian Institute of Management, Calcutta. He has worked for the BT Group in India in a variety of positions for over 17 years. |
| Mr. Pradeep Banerjee <i>Independent Director</i> | <ul style="list-style-type: none"> Mr. Pradeep Banerjee holds a bachelor's degree in technology (Chemical) from the Indian Institute of Technology, Delhi. Mr. Banerjee has held very senior positions at Hindustan Unilever Limited ("HUL"), including Executive Director-Supply Chain of HUL and Chairman of Unilever Nepal Limited. |
| Mr. Siraj Azmat Chaudhry <i>Independent Director</i> | <ul style="list-style-type: none"> Mr. Siraj A. Chaudhry holds an MBA from the Indian Institute of Foreign Trade (IIFT) and is a B.Com (Hons) from Shri Ram College of Commerce, University of Delhi. He has been in Business for 35 years, of which 20 years have been in leadership roles, building, turning around, acquiring, and divesting businesses in the agriculture and Food space |
| Ms. Ameeta Chatterjee <i>Independent Director</i> | <ul style="list-style-type: none"> Ms. Ameeta Chatterjee is Bachelors in Commerce from Lady Sriram College for Women, Delhi University, and is a management graduate from the Indian Institute of Management, Bangalore. Ms. Chatterjee has over 23 years of corporate experience in developing, managing, financing, and executing projects for the corporate sector in India and the UK. |
| Mr. Priyavrat Bhartia <i>Director</i> | <ul style="list-style-type: none"> Mr. Priyavrat Bhartia has around 26 years of industry experience. He holds a Bachelor's Degree in Economics from Dartmouth College, USA, and Masters in Business Administration from Stanford University, USA. At present, he is Managing Director of Jubilant Pharmova Limited. |
| Ms. Aashti Bhartia <i>Director</i> | <ul style="list-style-type: none"> Ms. Aashti Bhartia is a seasoned professional with over 15 years of experience in corporate governance and strategic leadership. She has served as a Non-Executive Director at Jubilant FoodWorks Limited since May 2017. |

Key Risks & Mitigation

Execution & Scale-Up Risk:

Jubilant Ingrevia is transitioning from a commodity-heavy portfolio to higher-value specialty chemicals, CDMO services, and human-grade nutrition ingredients. This strategy requires the timely completion of capex projects, regulatory approvals, customer audits, and commercial scale-up. Any delays in commissioning, slower-than-expected customer onboarding, or lower initial utilisation could defer revenue ramp-up and margin improvement, impacting return ratios. However, the company follows a phased and modular capex approach, prioritising high-visibility projects with confirmed customer interest. Long-term CDMO contracts with committed volumes provide baseline utilisation visibility and reduce demand uncertainty for new assets.

Cyclical in Chemical Intermediates:

The chemical intermediates segment (acetic anhydride, ethyl acetate, acetyl derivatives) remains exposed to global supply-demand imbalances, paracetamol demand cycles, and competitive pricing from low-cost producers. Prolonged weakness in pharma or oversupply could suppress realisations and dilute consolidated margins. However, the company is strategically rebalancing its revenue toward specialty chemicals, CDMO, and nutrition, which have structurally higher margins and longer customer contracts.

Capital Allocation and Cash Flow Risk:

Sustained investment in specialty chemicals, CDMO, and nutrition capacity requires significant capital outlay. If project ramp-ups lag expectations or industry conditions weaken, free cash flow generation could come under pressure, affecting balance sheet flexibility. JIL is looking to fund majority of growth capex through internal accruals, limiting leverage build-up.

Regulatory and Compliance Risk:

Operations span regulated sectors such as pharmaceuticals, food-grade nutrition, and agrochemicals. Changes in environmental norms, safety standards, product registrations, or export regulations could increase compliance costs, delay shipments, or restrict market access. The company's manufacturing facilities are designed to meet global regulatory standards, enabling continued access to regulated markets.

Demand Slowdown and Macroeconomic Risk:

Agrochemicals and industrial chemicals are sensitive to farm economics, weather patterns, inventory cycles, and global macro conditions. A prolonged slowdown could impact volumes and pricing, particularly in export markets. JIL is focusing on product and geographical diversification to reduce such risks.

Customer and Product Concentration Risk:

Certain specialty molecules and CDMO contracts account for a meaningful portion of segment revenues. Any loss of a large customer, delay in contract renewal, or shift in client sourcing strategy could create short-term volatility. The company tries to mitigate this risk by continuous expansion of the product pipeline and molecule portfolio across agrochem, pharma, and nutrition segments.

Foreign Exchange and Financial Market Risk:

A significant portion of revenue is export-linked, exposing earnings to currency volatility. In addition, higher global interest rates could increase borrowing costs. The Company follows a natural hedge-driven currency risk mitigation policy to the extent possible. Any residual risk is evaluated, and appropriate risk mitigating steps are planned, including but not limited to entering into forward contracts. The Company has clarified that it does not have material risk exposure in any commodity.

The company takes strategic steps along with traditional mitigation mechanisms to address conventional as well as emerging risks.

Outlook & Valuation

Entering a new growth phase – Initiate with BUY.

JIL embarked on a new growth path with the announcement of its Pinnacle 3.4.5 vision strategy last year. Under this strategy, the company aims to triple its revenue and quadruple its EBITDA over a five-year horizon. In line with this roadmap, over the past year, the company has made visible progress across key areas, forming the foundation for sustained long-term growth. Simultaneously, it is undertaking measures to mitigate near-term headwinds and ensure stability in the existing business.

JIL currently has a pipeline of more than 100 new opportunities, including 16 new molecules with a peak revenue potential of Rs 1,400 Cr. Large agro order commenced dispatches in Q4FY26, which is projected to generate revenues of \$300 Mn over five years. The company is also witnessing increased customer traction in the CDMO business across Pharma, Agro, Industrial, and Cosmetics/Nutrition segments, while making steady progress in emerging growth areas such as cosmetics and semiconductor chemicals. Although the Chemical Intermediates segment continues to face global headwinds, during the latest quarter, JIL reported higher domestic market volumes, supported by a modest uptick in agrochemicals and the paracetamol end-use segment. Despite continued pricing pressure and rising raw material costs, improving momentum in Acetic Acid indicates a potential upward trend going ahead.

With a clear growth vision, strategic capex, product portfolio expansion, and a sustained focus on cost efficiencies, JIL appears well-positioned to deliver profitable growth over the coming years. Accordingly, we estimate Revenue/EBITDA/PAT CAGR of 13%/20%/22% over FY25–FY28E. Given the differentiated nature of the business segments, We value the stock on an SOTP basis, assigning segment-wise EV/EBITDA multiples aligned with respective growth trajectories. This results in a target price of Rs. 800/per share, implying an upside of 21% from the CMP. We, therefore, initiate coverage on the stock with a BUY recommendation.

A clear near-term revenue visibility, backed by strategic steps for long-term growth justifies higher valuations.

| | FY28E EBITDA (Rs. In Cr) | EV/EBITDA Target Multiple (x) | Enterprise Value (Rs. In Crs) |
|----------------------------------|--------------------------|-------------------------------|-------------------------------|
| Specialty Chemicals | 719 | 15 | 10,784 |
| Nutrition & Health Solutions | 156 | 10 | 1,561 |
| Chemical Intermediates | 132 | 8 | 1,055 |
| Total | | | 13,401 |
| Gross Debt | | | 764 |
| Cash and Cash Equivalents | | | 99 |
| Market Cap (Rs. Cr) | | | 12,736 |
| No of shares (Cr) | | | 15.9 |
| Target Price (Rs/share) | | | 800 |

Industry Dynamics

The global specialty chemicals industry is witnessing steady structural expansion, with demand expected to compound at around mid-single digit rates over the medium term. In FY 2025, the global chemical industry operated at a complex inflection point, with growth moderating to low single digits as it faced headwinds from overcapacity, fluctuating energy prices, and stringent environmental regulations. However, India's chemical sector is projected to continue growing, driven by robust domestic demand and an emerging role as a preferred "China+1" sourcing hub.

Specialty Chemicals

Specialty chemicals sector deals with low-volume, high-value products tailored for performance, which are critical enablers of innovation and competitiveness. The global specialty chemicals market is expected to grow at a 5.0% CAGR, serving as a critical enabler for innovation in pharmaceuticals, agrochemicals, and electronics.

Growth is currently fueled by resurgence in agrochemical demand as global destocking concludes, as well as resilient needs for pharmaceutical intermediates from regulated markets like North America and Europe. Key industry trends include:

- **Technology Integration:** The adoption of flow chemistry, catalysis, and digital optimization is accelerating high-purity molecule development.
- **Sustainability Tailwinds:** Regulatory pressure is driving a shift toward greener, bio-based raw materials and clean-process engineering. Pyridine, as a bio-derived intermediate, offers superior efficacy and safety for both human and agricultural applications – leading to increasing preference for such products.
- **Sector-Specific Growth:** While the broader chemicals segment has seen significant demand and price volatility, some of the specialty products like pyridine derivatives have seen a steady growth. After experiencing a downturn in the last few years, agrochemical intermediates are expected to see a positive momentum going ahead.

Looking forward, the industry is expected to undergo a structural evolution from volume-led commodity manufacturing toward value-accretive, platform-based CDMO models. This transition focuses on innovation and the establishment of circular, bio-integrated supply chains to meet increasingly stringent global ESG expectations.

Custom Development & Manufacturing Organisation (CDMO)

The global pharmaceutical CDMO market has expanded into a large, structurally high-growth industry, driven by increasing outsourcing across drug discovery, development and commercial manufacturing. The market is expected to nearly double over the current decade, supported by rising R&D intensity, regulatory complexity and the need for faster product commercialisation. The global market for Pharmaceutical Custom Development and Manufacturing Organisations (CDMOs) was valued at \$180.3 Bn in 2020 and is projected to reach \$319.6 Bn by 2029, growing at a CAGR of 9.7%. The key trends supporting this growth are:

In parallel, India's specialty chemicals industry is growing at a significantly faster pace than global averages, with the domestic CDMO segment emerging as one of the fastest-expanding sub-segments, reflecting strong client migration toward Indian manufacturing partners. The growth of Indian CDMO industry is supported by:

- Diversification of Global Supply Chains to reduce ("China+1" supply-chain diversification strategy)
- Availability of skilled workforce, making suitable for R&D/testing work
- Lower cost compared to the European and the USA
- Regulatory tailwinds in form of incentive schemes and simplification of regulatory processes

The global chemical industry is undergoing a structural shift toward high-value specialty chemicals, CDMO-led outsourcing, and sustainable bio-based solutions, with India emerging as a key growth hub supported by the "China+1" supply chain strategy and strong domestic demand.

Nutrition & Health Solutions Industry

The Nutrition & Health Solutions is segmented into:

- Animal Nutrition: Feed grade Niacinamide, Niacin, Choline Chloride and 18+ branded Specialty formulations.
- Human Nutrition: fortified food ingredients, nutraceuticals, medical nutrition
- Personal Care and Cosmetics: Anti-ageing and skin-lightening formulations
- Pharmaceuticals: Therapeutic niacinbased cardiovascular and lipidlowering drugs

The industry is benefiting from strong global demand across both human and animal nutrition markets. In human health, nutraceuticals and dietary supplements are expanding rapidly, supported by rising health awareness, evolving dietary patterns, growing adoption of fortified foods and supportive regulatory frameworks.

Vitamins such as niacin (Vitamin B3) form an essential component of this ecosystem, with applications extending across nutritional supplements, functional foods, cosmetics, pharmaceuticals and energy beverages due to their role in cellular energy metabolism.

In animal nutrition, vitamin supplementation is becoming increasingly critical as livestock farming intensifies and feed efficiency standards rise. B-complex vitamins are particularly important for monogastric animals, supporting growth, immunity and productivity in poultry, aquaculture, dairy and swine segments.

India is emerging as a key global exporter of vitamins, given the existing ecosystem which can scaled/modified to suit global needs and the inherent cost advantages compared to developed economies. However, the expertise and ability to comply with stringent global standards are a critical factor impacting the sourcing decisions of global innovators.

Chemical Intermediates Industry:

Chemical intermediates form the backbone of multiple industrial value chains, serving as essential building blocks for pharmaceuticals, agrochemicals, polymers, and consumer products. Their availability directly influences production continuity, cost structures, and supply reliability across downstream sectors.

As discussed in the earlier section, chemical intermediates are typically supplied in bulk quantities and are highly commoditized. While these ingredients are critical across industries, demand for such products is largely derived from the demand for the end products of their customers. Consequently, the sector remains exposed to cyclical trends, which are in turn linked to global macroeconomic developments.

Growth for the sector is therefore contingent upon: a) expansion in the Pharmaceutical industry, particularly Paracetamol in the case of JIL, b) demand for solvents used in Paints, Coatings and Adhesives, c) trends in the Agrochemical sector, and d) increasing demand for sustainable and bio-based alternatives.

Note: Market demand and growth-related estimates cited in this section are primarily sourced from the company's annual report for FY25.

Financials (Consolidated)

Profit & Loss

(Rs. Cr)

| Y/E March | FY24 | FY25 | FY26E | FY27E | FY28E |
|--|--------------|--------------|--------------|--------------|--------------|
| Net Sales | 4,136 | 4,178 | 4,329 | 5,058 | 5,982 |
| COGS | 2,143 | 2,107 | 2,268 | 2,491 | 2,886 |
| Employee Cost | 384 | 418 | 430 | 485 | 553 |
| Other Expenses | 1,188 | 1,133 | 1,084 | 1,358 | 1,656 |
| Total Expenditure | 3,715 | 3,659 | 3,782 | 4,334 | 5,095 |
| EBITDA | 421 | 519 | 546 | 724 | 887 |
| EBITDA Margin % | 10.2% | 12.4% | 12.6% | 14.3% | 14.8% |
| Other Income | 35 | 38 | 41 | 39 | 40 |
| Depreciation | 136 | 158 | 169 | 213 | 245 |
| EBIT | 320 | 399 | 419 | 550 | 682 |
| Finance Cost | 53 | 56 | 57 | 72 | 81 |
| Share of profit/(loss) of an associate | 0.0 | (0.0) | (0.2) | - | - |
| PBT | 268 | 344 | 375 | 478 | 601 |
| Tax | 85 | 92 | 89 | 119 | 150 |
| Tax Rate % | 31.7% | 26.9% | 23.8% | 25.0% | 25.0% |
| PAT | 183 | 251 | 286 | 358 | 451 |
| EPS | 11.5 | 15.8 | 18.0 | 22.5 | 28.3 |

Source: Company, Axis Securities Research

Balance Sheet

(Rs. Cr)

| Y/E March | FY24 | FY25 | FY26E | FY27E | FY28E |
|--------------------------------------|--------------|--------------|--------------|--------------|--------------|
| Share Capital | 16 | 16 | 16 | 16 | 16 |
| Reserves & Surplus | 2,722 | 2,911 | 3,197 | 3,556 | 4,006 |
| Total Equity Capital | 2,737 | 2,927 | 3,213 | 3,571 | 4,022 |
| Long Term Borrowings | 426 | 363 | 553 | 585 | 498 |
| Other Financial Liabilities | - | 44 | 44 | 44 | 44 |
| Long Term Provisions | 65 | 67 | 67 | 67 | 67 |
| Defered Tax Liabilities (Net) | 214 | 225 | 225 | 225 | 225 |
| Total Non-Current Liabilities | 708 | 704 | 893 | 925 | 838 |
| Borrowings | 307 | 393 | 404 | 472 | 559 |
| Trade Payables | 767 | 815 | 857 | 949 | 1,107 |
| Other Financial Liabilities | 145 | 125 | 125 | 125 | 125 |
| Other Current Liabilities | 23 | 16 | 16 | 16 | 16 |
| Short Term Provisions | 18 | 21 | 21 | 21 | 21 |
| Current Tax Liabilities | 23 | 29 | 29 | 29 | 29 |
| Total Current Liability | 1,286 | 1,401 | 1,454 | 1,613 | 1,859 |
| Total Liabilities | 1,994 | 2,105 | 2,347 | 2,538 | 2,697 |
| Total Equity + Liabilities | 4,732 | 5,032 | 5,560 | 6,110 | 6,719 |
| Assets | | | | | |
| Inventories | 941 | 943 | 1,025 | 1,140 | 1,336 |
| Trade Receivable | 572 | 607 | 581 | 665 | 770 |
| Cash and Equivalents | 79 | 69 | 111 | 74 | 27 |
| Bank Balance | 1 | 29 | 29 | 29 | 29 |
| Income Tax Assets | 41 | 41 | 41 | 41 | 41 |
| Other Current Assets | 146 | 147 | 147 | 147 | 147 |
| Total Current Assets | 1,780 | 1,853 | 1,950 | 2,112 | 2,367 |
| Property, plant and equipment | 2,478 | 2,516 | 3,172 | 3,660 | 4,115 |
| Capital Work in Progress | 331 | 525 | 300 | 200 | 100 |
| Right-of-Use Assets | 41 | 42 | 42 | 42 | 42 |
| Intangible assets | 20 | 23 | 23 | 23 | 23 |
| Financial Assets : Investments | 10 | 14 | 14 | 14 | 14 |
| Deferred tax assets (net) | 13 | 17 | 17 | 17 | 17 |
| Other Non Current Assets | 32 | 23 | 23 | 23 | 23 |
| Total Non-Current Assets | 2,952 | 3,179 | 3,610 | 3,997 | 4,352 |
| Total Assets | 4,732 | 5,032 | 5,560 | 6,110 | 6,719 |

Source: Company, Axis Securities Research

Cash Flow
(Rs. Cr)

| Y/E March | FY24 | FY25 | FY26E | FY27E | FY28E |
|--|--------------|--------------|--------------|--------------|--------------|
| PBT | 268 | 344 | 375 | 478 | 601 |
| Depreciation & Amortization | 136 | 158 | 169 | 213 | 245 |
| Chg in Working cap | 6 | 23 | (13) | (107) | (143) |
| Direct tax paid | (46) | (80) | (89) | (119) | (150) |
| Others | 66 | 64 | 57 | 72 | 81 |
| Cash From Operating Activities | 430 | 508 | 498 | 536 | 633 |
| Chg in Gross Block | (566) | (352) | (600) | (600) | (600) |
| Chg in Investments | (3) | (44) | - | - | - |
| Interest Received | 1 | 3 | - | - | - |
| Cash Flow from Investing Activities | (569) | (393) | (600) | (600) | (600) |
| Proceeds / (Repayment) of Borrowings (Net) | 300 | 7 | 190 | 32 | (87) |
| Finance Cost paid | (68) | (74) | (57) | (72) | (81) |
| Dividends paid | (79) | (80) | - | - | - |
| Others | (9) | 18 | 10 | 68 | 87 |
| Cash from Financing Activities | 144 | (129) | 143 | 28 | (81) |
| Opening Cash & Cash Equivalents | 73 | 79 | 69 | 111 | 74 |
| Chg in cash | 1 | 4 | - | - | - |
| Closing Cash & Cash Equivalent | 79 | 69 | 111 | 74 | 27 |


Source: Company, Axis Securities Research

Ratio Analysis
(%)

| Y/E March | FY24 | FY25 | FY26E | FY27E | FY28E |
|-----------------------------|------|------|-------|-------|-------|
| Growth (%) | | | | | |
| Net Sales | -13% | 1% | 4% | 17% | 18% |
| EBITDA | -23% | 23% | 5% | 33% | 22% |
| APAT | -41% | 37% | 14% | 25% | 26% |
| Profitability (%) | | | | | |
| EBITDA Margin | 10% | 12% | 13% | 14% | 15% |
| Adj. PAT Margin | 4% | 6% | 7% | 7% | 8% |
| ROCE | 10% | 11% | 11% | 13% | 15% |
| ROE | 7% | 9% | 9% | 11% | 12% |
| Per Share Data (Rs.) | | | | | |
| Adj. EPS | 11.5 | 15.8 | 18.0 | 22.5 | 28.3 |
| BVPS | 172 | 184 | 202 | 224 | 253 |
| Valuations (X) | | | | | |
| PER | 57.3 | 41.7 | 36.7 | 29.3 | 23.3 |
| P/BV | 3.8 | 3.6 | 3.3 | 2.9 | 2.6 |
| EV / EBITDA | 26.5 | 21.5 | 20.7 | 15.8 | 13.0 |
| EV / Net Sales | 2.7 | 2.7 | 2.6 | 2.3 | 1.9 |
| Turnover Days | | | | | |
| Asset Turnover | 1 | 1 | 1 | 1 | 1 |
| Inventory days | 168 | 163 | 158 | 159 | 157 |
| Debtors days | 48 | 52 | 50 | 45 | 44 |
| Creditors days | 70 | 67 | 69 | 132 | 130 |
| Working Capital Days | 146 | 148 | 139 | 71 | 70 |
| Gearing Ratio | | | | | |
| Debt to Equity (x) | 0.16 | 0.12 | 0.17 | 0.16 | 0.12 |

Source: Company, Axis Securities Research

Jubilant Ingrevia Ltd. Price Chart and Recommendation History



| Date | Reco | TP | Research |
|-----------|------|-----|---------------------|
| 22-Apr-26 | BUY | 800 | Initiating Coverage |
| | | | |

Source: Axis Securities Research

Axis Direct is the brand under Axis Securities Limited, which is a 100% subsidiary of Axis Bank Limited. Axis Bank Ltd. is a listed public company and one of India's largest private sector banks, and has its various subsidiaries engaged in businesses of Asset management, NBFC, Merchant Banking, Trusteeship, Venture Capital, Stock Broking, the details in respect of which are available on www.axisbank.com.

Axis Securities Limited is registered as a

- Stock Broker, Depository Participant, Portfolio Manager, Investment Adviser and Research Analyst with the Securities and Exchange Board of India
- Corporate Agent with Insurance Regulatory and Development Authority of India
- Point of Presence with Pension Fund Regulatory and Development Authority
- Distributor for Mutual Funds with AMFI

Registration Details:

SEBI Single Reg. No.- NSE, BSE, MSEI, MCX & NCDEX – INZ000161633 | SEBI Depository Participant Reg. No. IN-DP-403-2019 | Portfolio Manager Reg. No.- INP000000654 | Investment Advisor Reg No. INA000000615 | SEBI-Research Analyst Reg. No. INH000000297 | IRDA Corporate Agent (Composite) Reg. No. CA0073| PFRDA – POP Reg. No. POP387122023 | Mutual Fund Distributor ARN- 64610.

Compliance Officer Details: Name – Mr Rajiv Kejriwal, Tel No. – 022-68555574, Email id – compliance.officer@axisdirect.in;

Registered Office Address – Axis Securities Limited, Unit No.002, Building- A, Agastya Corporate Park, Piramal Realty, Kamani Junction, Kurla (W), Mumbai – 400070.

Administrative office address: Axis Securities Limited, Aurum Q Parc, Q2 Building, Unit No. 1001, 10th Floor, Level – 6, Plot No. 4/1 TTC, Thane – Belapur Road, Ghansoli, Navi Mumbai, Pin Code – 400710.

In case of any grievances, please call us at 022-40508080 or write to us at helpdesk@axisdirect.in.

We hereby declare that our activities have neither been suspended nor have we defaulted with any stock exchange authority with whom we are registered in the last five years. However, SEBI, Exchanges, Clearing Corporations and Depositories, etc. have conducted the routine inspection and based on their observations have issued advice/warning/show cause notices/deficiency letters/ or levied penalty or imposed charges for certain deviations observed in inspections or in the normal course of business, as a Stock Broker/Depository Participant/Portfolio Manager. We have not been debarred from doing business by any Stock Exchange/SEBI or any other authorities; nor has our certificate of registration been cancelled by SEBI at any point in time.

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.

By referring to any particular sector, Axis Securities does not provide any promise or assurance of a favourable view for a particular industry or sector or business group in any manner.

Registration granted by SEBI, membership of RAASB (in case of RA's) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk-free return to the investors. Our research should not be considered as an advertisement or advice, professional or otherwise. This research report and its respective content by Axis Securities made available on this page or otherwise do not constitute an offer to sell or purchase or subscribe for any securities or solicitation of any investments or investment services for the residents of Canada and/or the USA or any jurisdiction where such an offer or solicitation would be illegal.

Subject company(ies) may have been clients during the twelve months preceding the date of distribution of the research report. Derivatives are a sophisticated investment device. The investor is requested to take into consideration all the risk factors before actually trading in derivative contracts.

Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a judgment of its original date of publication by ASL and are subject to change without notice. The price, value of and income from any of the securities or financial instruments mentioned in this report can fall as well as rise. The value of securities and financial instruments is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities or financial instruments.

The information and opinions in this report have been prepared by Axis Securities and are subject to change without notice. The report and information contained herein are strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of Axis Securities. The report must not be used as a singular basis for any investment decision. The views herein are of a general nature and do not consider the risk appetite, investment objective or the particular circumstances of an individual investor. The investor is requested to take into consideration all the risk factors, including their financial condition, suitability to risk return profile and the like and take professional advice before investing.

While we would endeavour to update the information herein on a reasonable basis, Axis Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent Axis Securities from doing so. Non-rated securities indicate that the rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or Axis Securities policies, in circumstances where Axis Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained in good faith from public sources and sources believed to be reliable, but no independent verification has been made, nor is its accuracy or completeness guaranteed. This report and information herein are solely for informational purposes and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. Axis Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and/or tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and the needs of the specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. Axis Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see the Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ

materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Axis Securities or its associates might have managed or co-managed a public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months. Axis Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. Axis Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking, or brokerage services from the companies mentioned in the report in the past twelve months. Axis Securities encourages independence in research report preparation and strives to minimise conflict in the preparation of research reports. Axis Securities or its associates, or its analysts, did not receive any compensation or other benefits from the companies mentioned in the report or a third party in connection with the preparation of the research report. Accordingly, neither Axis Securities nor Research Analysts and/or their relatives have any material conflict of interest at the time of publication of this report. Please note that Axis Securities has a proprietary trading desk. This desk maintains an arm's length distance from the Research team, and all its activities are segregated from Research activities. The proprietary desk operates independently, potentially leading to investment decisions that may deviate from research views.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

Research Analyst may have served as an officer, director or employee of the subject company(ies). Axis Securities or Research Analysts, or their relatives, do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report. Since associates of Axis Securities and Axis Securities as an entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one per cent or more or other material conflicts of interest in various companies, including the subject company/companies mentioned in this report. Axis Securities may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report. Certain transactions-including those involving futures, options and other derivatives as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. Reports based on technical analysis centre on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals.

We and our affiliates/associates, officers, directors, and employees, Research Analyst(including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company (ies) discussed herein or act as advisor or lender/borrower to such company (ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of Research Report or at the time of public appearance. Axis Securities may have proprietary long/short positions in the above-mentioned scrip(s) and therefore may be considered as interested. This should not be construed as an invitation or solicitation to do business with Axis Securities. Axis Securities is also a Portfolio Manager. Portfolio Management Team (PMS) takes its investment decisions independently of the PCG research, and accordingly, PMS may have positions contrary to the PCG research recommendation.

This research report is issued in India by Axis Securities Limited in accordance with the Securities and Exchange Board of India (Research Analysts) Regulations, 2014. It is intended solely for persons residing in India. The report is not directed at or intended for distribution to, or use by, any person or entity resident in the United States of America, Canada, or in any jurisdiction where such distribution, publication, availability, or use would be contrary to applicable securities laws, including the U.S. Securities Exchange Act of 1934, regulations of the U.S. Securities and Exchange Commission (SEC), and regulations of the Canadian Securities Administrators (CSA).

RATING SCALE: Definitions of ratings

| Ratings | Expected absolute returns over 12 – 18 months |
|----------------|--|
| BUY | More than 10% |
| HOLD | Between 10% and -10% |
| SELL | Less than -10% |
| NOT RATED | We have forward-looking estimates for the stock, but we refrain from assigning a valuation and recommendation. |
| UNDER REVIEW | We will revisit our recommendation, valuation and estimates on the stock following recent events. |
| NO STANCE | We do not have any forward-looking estimates, valuations or recommendations for the stock. |

Note: Returns stated in the rating scale are our internal benchmark.